Biomea Fusion BMEA 深 沪
等待开盘 08-18 09:30:00 美东时间
1.35
+0.030
+2.27%
华盛通- 最 高1.39
- 今 开1.32
- 成交量 63.39万股
- 最 低 1.30
- 昨 收 1.32
- 总市值 9785.32万
- 52周最高 2.99
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 0.8719
- 委 比 -91.01%
- 总股本 7248.39万
- 历史最高 43.69
- 量 比 1.57
- 振 幅 6.82%
- 历史最低 0.8719
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has initiated a new arm of the OPAL study to evaluate the combination of icovamenib and low-dose semaglutide in overweight or obese individuals without type 2 diabetes. The randomized, double-blind study aims to assess the impact on weight loss, physical function, body composition, muscle health, and metabolic outcomes. The primary endpoint will be evaluated at Week 24. Preclinical data suggests icovamenib enhances semaglutide's eff...
08-13 11:00
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of $(0.51) per share from the same period last year.
08-06 06:11
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported Q2 2026 financial results and business updates, including ongoing Phase II clinical trials for icovamenib in T2D patients and collaboration with Leicester University for obesity research. The company also expanded its BMF-650 obesity trial and expects initial weight loss data by Q3 2026. Cash runway extends into Q2 2027.
08-05 20:05
Biomea Fusion Partners With The University Of Leicester For Ongoing Platform Research Study Titled 'Investigating And Optimizing Physical Function With Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial'
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking Preclinical Findings
06-03 20:03
Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 78.75 percent increase over losses of $(0.80) per share from the
05-12 05:16
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Citizens Initiates Coverage On Biomea Fusion with Market Outperform Rating, Announces Price Target of $9
Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Market Outperform rating and announces Price Target of $9.
05-05 20:33
Biomea Fusion Reveals 52-Week Results From Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment; In Patients Diagnosed Within 0-3 Years, Treatment With Icovamenib 200 Mg Once Daily For 12 Weeks Resulted In A 52% Increase In Mean C-peptide Area Under The Curve At Week 12
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week
04-28 05:43
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
